everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...8485868788899091929394...132133»
  • ||||||||||  Afinitor (everolimus) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS
    Clinical, Journal:  Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study. (Pubmed Central) -  Jun 15, 2019   
    Agreement was achieved for 19 of the proposed 25 statements (76%). When making a decision about the treatment option, considering the efficiency and response rate to previous treatment, drug's toxicity and the patients' clinical features are very relevant.
  • ||||||||||  Afinitor (everolimus) / Novartis
    Journal, Combination therapy:  Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia. (Pubmed Central) -  Jun 15, 2019   
    The response to Everolimus was influenced by TKI treatment, with a better response in samples from patients under 2nd and 3rd generation TKI and with less toxicity to lymphocytes. Our results reveal that Everolimus induce cell death in CML cells sensitive and resistant to Imatinib, with low cytotoxicity to normal cells, suggesting that Everolimus could be an alternative targeted therapeutic approach in CML patients, even in cases of Imatinib resistance.
  • ||||||||||  Afinitor (everolimus) / Novartis
    Clinical, Journal:  Long-Term Clinical and Angiographic Outcomes After Implantation of New-Generation Drug-Eluting Stents for Patients on Maintenance Hemodialysis. (Pubmed Central) -  Jun 14, 2019   
    ...This study aims to investigate the long-term clinical and angiographic outcomes after new-generation DES implantation for hemodialysis patients.We retrospectively enrolled 91 consecutive patients (118 lesions) who underwent successful new-generation DES (everolimus-, zotarolimus-, and biolimus-eluting stents) implantation for the first time...The serum calcium level was significantly higher in the MACCE group (9.34 ± 0.92 mg/dL versus 8.77 ± 0.88 mg/dL; P = 0.004). The multivariate Cox proportional hazards model revealed that the serum calcium level (hazard ratio, 1.86; 95% confidence interval [CI]: 1.26-2.77; P = 0.002), suboptimal (over 55 mg/dL) calcium-phosphorus product (hazard ratio, 3.27; 95% CI: 1.41-7.61; P = 0.006) and the coexistence of peripheral artery disease (hazard ratio, 3.15; 95% CI: 1.49-6.65; P = 0.003) were independent predictors of MACCE.For hemodialysis patients, MACCE remains a frequent occurrence after new-generation DES implantation and is associated with calcium-phosphate metabolism and peripheral artery disease.
  • ||||||||||  Avastin (bevacizumab) / Roche, Afinitor (everolimus) / Novartis
    Retrospective data, Journal:  Treatments for patients with advanced neuroendocrine tumors: a network meta-analysis. (Pubmed Central) -  Jun 14, 2019   
    PRRT is likely to be the most preferable treatment for patients with advanced well-differentiated NETs. SSA+bevacizumab and SSA+IFN-α also seem to be more effective regimens with limited risk of SAEs.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Afinitor (everolimus) / Novartis
    Review, Journal:  Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome. (Pubmed Central) -  Jun 14, 2019   
    This review provides a discussion of the recent and future promising therapeutic approaches in the management of advanced MF/SS. These include mogamulizumab, brentuximab vedotin, alemtuzumab, immune checkpoint inhibitors, IPH4102 (anti-KIR3DL2 antibody), histone deacetylase inhibitors (vorinostat, romidepsin, panobinostat, belinostat, and resminostat), pralatrexate, forodesine, denileukin diftitox, duvelisib, lenalidomide, and everolimus.
  • ||||||||||  Imbruvica (ibrutinib) / AbbVie, J&J
    Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors (clinicaltrials.gov) -  Jun 12, 2019   
    P1b/2,  N=348, Recruiting, 
    These include mogamulizumab, brentuximab vedotin, alemtuzumab, immune checkpoint inhibitors, IPH4102 (anti-KIR3DL2 antibody), histone deacetylase inhibitors (vorinostat, romidepsin, panobinostat, belinostat, and resminostat), pralatrexate, forodesine, denileukin diftitox, duvelisib, lenalidomide, and everolimus. N=261 --> 348 | Trial completion date: Jun 2019 --> May 2021 | Trial primary completion date: Feb 2019 --> May 2021
  • ||||||||||  Taltorvic (ridaforolimus) / Takeda, Merck (MSD), Afinitor (everolimus) / Novartis
    Journal:  The EluNIR Ridaforolimus Eluting Coronary Stent System. (Pubmed Central) -  Jun 9, 2019   
    The stent has thin struts with variable widths and a delivery catheter with a spring tip. These characteristics may explain the good angiographic and clinical results of this stent, which were non-inferior to the FDA approved Medtronic Resolute stent DES.
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Trial completion date, Trial primary completion date, Metastases:  Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) -  Jun 4, 2019   
    P=N/A,  N=30, Recruiting, 
    Our limited single center experience shows encouraging response to use of somatostatin analogs, azithromycin, and everolimus in the management of debilitating DIPNECH associated symptoms. Trial completion date: May 2019 --> May 2020 | Trial primary completion date: May 2019 --> May 2020
  • ||||||||||  everolimus / Generic mfg.
    Preclinical, Journal:  In Vivo Evaluation of Dual-Targeted Nanoparticles Encapsulating Paclitaxel and Everolimus. (Pubmed Central) -  May 31, 2019   
    While maintaining anti-tumor efficacy, the levels of body weight loss were significantly lower (p < 0.0001) and the overall degree of neurotoxicity was reduced with Dual-NP treatment in comparison to the free-drug combination when administered at an equivalent dose of PTX. This study suggests that Dual-NPs present a promising platform for the delivery of the PTX and EVER combination with the potential to reduce severe PTX-induced toxicities and in turn, improve quality of life for patients with BC.
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer (clinicaltrials.gov) -  May 30, 2019   
    P2,  N=48, Active, not recruiting, 
    This study suggests that Dual-NPs present a promising platform for the delivery of the PTX and EVER combination with the potential to reduce severe PTX-induced toxicities and in turn, improve quality of life for patients with BC. Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Jan 2020
  • ||||||||||  Afinitor (everolimus) / Novartis
    Clinical, Clinical data, Journal:  Primary hepatic angiosarcoma and liver transplantation: Radiological, surgical, histological findings and clinical outcome. (Pubmed Central) -  May 30, 2019   
    Because of the histological findings, tacrolimus was switched to everolimus as the main immunosuppressive drug one month after LT...Consequently, HAS remains an absolute contraindication to LT because of the poor outcome. If LT has been performed for incidental HAS, new molecular therapies (e.g. vascular endothelial growth factor antagonists) should be considered immediately after LT to improve the outcome.
  • ||||||||||  Afinitor (everolimus) / Novartis
    Review, Journal:  Renal Protection Strategies after Heart Transplantation. (Pubmed Central) -  May 30, 2019   
    This review outlines the recent results of using these renal protection strategies including their drawbacks. We also discuss alternative approaches to optimized individual immunosuppressive therapies after HTx.
  • ||||||||||  metformin / Generic mfg., everolimus / Generic mfg., exemestane / Generic mfg.
    Enrollment change, Metastases:  Exemestane-RAD001-Metformin (clinicaltrials.gov) -  May 29, 2019   
    P2,  N=23, Terminated, 
    Treatment with mTOR inhibitors can reverse graft dysfunction in approximately half of patients. N=40 --> 23
  • ||||||||||  everolimus / Generic mfg.
    Biomarker, Review, Journal:  Targeting the PI3K pathway in cancer: are we making headway? (Pubmed Central) -  May 24, 2019   
    Finally, considering that oncogenic activation of the PI3K-AKT-mTOR pathway often occurs alongside pro-tumorigenic aberrations in other signalling networks, rational combinations are also needed to optimize the effectiveness of treatment. Herein, we review the current experience with anticancer therapies that target the PI3K-AKT-mTOR pathway.
  • ||||||||||  Afinitor (everolimus) / Novartis, Nexavar (sorafenib) / Bayer, Amgen
    Retrospective data, Journal:  Antitumor effect of sorafenib and mTOR inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence. (Pubmed Central) -  May 24, 2019   
    Our clinical result of mTORi administration showed improved post-recurrence survival, thus administering mTORi in LT recipients with HCC recurrence appears worthwhile. However, antitumor effect of sorafenib on post-transplant recurrence was not determined in this retrospective study, thus requiring further studies with early start of sorafenib administration.
  • ||||||||||  everolimus / Generic mfg.
    Enrollment closed, Metastases:  Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China (clinicaltrials.gov) -  May 24, 2019   
    P4,  N=49, Active, not recruiting, 
    Although the comprehensive immunomonitoring analysis performed in this study provides relevant information for the design of future immunotherapeutic approaches, the addition of metronomic cyclophosphamide to mRCC patients receiving everolimus cannot be recommended. Recruiting --> Active, not recruiting
  • ||||||||||  Afinitor (everolimus) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS
    Clinical, Journal:  Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients. (Pubmed Central) -  May 15, 2019   
    For patients who have failed prior transplant or are unsuitable for dose-intense approaches based on age or comorbidities, an individualized approach with sequential use of single agents such as brentuximab vedotin, PD-1 inhibitors, everolimus, lenalidomide, or conventional agents such as gemcitabine or vinorelbine, may result in prolonged survivals with minimal or modest effect on quality of life. Participation in clinical trials evaluating new approaches such as combination immune checkpoint inhibition, novel antibody-drug conjugates, or cellular therapies such as EBV-directed cytotoxic T-lymphocytes and chimeric antigen receptor T-cells offer additional options for eligible patients.
  • ||||||||||  Afinitor (everolimus) / Novartis
    Journal:  2-Oxonanonoidal Antibiotic Actinolactomycin Inhibits Cancer Progression by Suppressing HIF-1α. (Pubmed Central) -  May 15, 2019   
    More interestingly, low dose of ALM treatment enhanced the anti-tumor effect of Everolimus, an inhibitor of mTOR, suggesting its potential use in combination therapy of tumors, especially solid tumor patients. Thus, we identified a novel HIF-1α inhibitor from the metabolites of Streptomyces flavoretus, which shows promising anti-cancer potential.
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD), Torisel (temsirolimus) / Pfizer
    Trial completion date, Trial primary completion date, Epigenetic controller, Metastases:  Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer (clinicaltrials.gov) -  May 15, 2019   
    P1,  N=249, Active, not recruiting, 
    Trial completion date: Sep 2019 --> Sep 2020 Trial completion date: Mar 2019 --> May 2021 | Trial primary completion date: Mar 2019 --> May 2020